ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Mixed Results from Testosterone Therapy Study
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Jinzang" data-source="post: 63897" data-attributes="member: 12925"><p>Yesterday's post was put together quickly and didn't have a link to the studies themselves, which I prefer to do. So here's a link to the more concerning of the studies, on <a href="http://jamanetwork.com/journals/jama/fullarticle/2603929" target="_blank">TRT and arterial plaque increase</a>. The full text of the article is available, thanks JAMA. I'll refrain from comment, except to say it doesn't seem a badly designed or conducted study. Here are a few excerpts from the paper:</p><p></p><p>Double-blinded, placebo-controlled trial at 9 academic medical centers in the United States. The participants were 170 of 788 men aged 65 years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men assigned to placebo, 88 to testosterone) and symptoms suggestive of hypogonadism.</p><p></p><p>Of 170 men who were enrolled, 138 (73 receiving testosterone treatment and 65 receiving placebo) completed the study and were available for the primary analysis. Among the 138 men, the mean (SD) age was 71.2 (5.7) years, and 81% were white. At baseline, 70 men (50.7%) had a coronary artery calcification score higher than 300 Agatston units, reflecting severe atherosclerosis. For the primary outcome, testosterone treatment compared with placebo was associated with a significantly greater increase in noncalcified plaque volume from baseline to 12 months (from median values of 204 mm[SUP]3[/SUP] to 232 mm[SUP]3[/SUP] vs 317 mm[SUP]3[/SUP] to 325 mm[SUP]3[/SUP], respectively.</p><p></p><p>Testosterone was administered as a 1% gel in a pump bottle (AndroGel). Placebo gel was similar. The dose was initially 5 g/d and was adjusted, if necessary, on the basis of testosterone levels measured at a central laboratory (Quest Clinical Trials) at months 1, 2, 3, 6, and 9, to try to keep the serum concentration within the normal range for young men (280-873 ng/dL).</p><p></p><p>The sample size for this trial was initially estimated to be 400 men in the protocol of October 2010 but was later reduced to 140 men when the primary outcome was changed from total to noncalcified plaque volume, because the latter has a smaller standard deviation.</p><p></p><p>At baseline, noncalcified plaque volume showed considerable variability, and the median in the testosterone group (204 mm[SUP]3[/SUP] [interquartile range, 60 to 420 mm[SUP]3[/SUP]]) was somewhat lower than that in the placebo group (317 mm[SUP]3[/SUP] [interquartile range, 168 to 589 mm[SUP]3[/SUP]])</p><p></p><p>Exploratory analyses of the individual components of noncalcified plaque showed that testosterone treatment was associated with a significantly greater increase in fibrous plaque volume.</p><p></p><p>The change in noncalcified coronary artery plaque volume in men in the testosterone group was not associated with changes in levels of total testosterone (<em>r</em>&#8201;=&#8201;&#8722;0.04; <em>P</em>&#8201;=&#8201;.74), free testosterone (<em>r</em>&#8201;=&#8201;&#8722;0.006; <em>P</em>&#8201;=&#8201;.96), or estradiol (<em>r</em>&#8201;=&#8201;&#8722;0.08; <em>P</em>&#8201;=&#8201;.50).</p></blockquote><p></p>
[QUOTE="Jinzang, post: 63897, member: 12925"] Yesterday's post was put together quickly and didn't have a link to the studies themselves, which I prefer to do. So here's a link to the more concerning of the studies, on [URL="http://jamanetwork.com/journals/jama/fullarticle/2603929"]TRT and arterial plaque increase[/URL]. The full text of the article is available, thanks JAMA. I'll refrain from comment, except to say it doesn't seem a badly designed or conducted study. Here are a few excerpts from the paper: Double-blinded, placebo-controlled trial at 9 academic medical centers in the United States. The participants were 170 of 788 men aged 65 years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men assigned to placebo, 88 to testosterone) and symptoms suggestive of hypogonadism. Of 170 men who were enrolled, 138 (73 receiving testosterone treatment and 65 receiving placebo) completed the study and were available for the primary analysis. Among the 138 men, the mean (SD) age was 71.2 (5.7) years, and 81% were white. At baseline, 70 men (50.7%) had a coronary artery calcification score higher than 300 Agatston units, reflecting severe atherosclerosis. For the primary outcome, testosterone treatment compared with placebo was associated with a significantly greater increase in noncalcified plaque volume from baseline to 12 months (from median values of 204 mm[SUP]3[/SUP] to 232 mm[SUP]3[/SUP] vs 317 mm[SUP]3[/SUP] to 325 mm[SUP]3[/SUP], respectively. Testosterone was administered as a 1% gel in a pump bottle (AndroGel). Placebo gel was similar. The dose was initially 5 g/d and was adjusted, if necessary, on the basis of testosterone levels measured at a central laboratory (Quest Clinical Trials) at months 1, 2, 3, 6, and 9, to try to keep the serum concentration within the normal range for young men (280-873 ng/dL). The sample size for this trial was initially estimated to be 400 men in the protocol of October 2010 but was later reduced to 140 men when the primary outcome was changed from total to noncalcified plaque volume, because the latter has a smaller standard deviation. At baseline, noncalcified plaque volume showed considerable variability, and the median in the testosterone group (204 mm[SUP]3[/SUP] [interquartile range, 60 to 420 mm[SUP]3[/SUP]]) was somewhat lower than that in the placebo group (317 mm[SUP]3[/SUP] [interquartile range, 168 to 589 mm[SUP]3[/SUP]]) Exploratory analyses of the individual components of noncalcified plaque showed that testosterone treatment was associated with a significantly greater increase in fibrous plaque volume. The change in noncalcified coronary artery plaque volume in men in the testosterone group was not associated with changes in levels of total testosterone ([I]r[/I] = −0.04; [I]P[/I] = .74), free testosterone ([I]r[/I] = −0.006; [I]P[/I] = .96), or estradiol ([I]r[/I] = −0.08; [I]P[/I] = .50). [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Mixed Results from Testosterone Therapy Study
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top